Document is current
Any future updates will be listed below
-
Authors
Singhi, Eric K. https://orcid.org/0000-0001-5918-9168
Nadler, Eric S. https://orcid.org/0000-0003-3727-9247
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 11 July 2025
Accepted: 2 December 2025
First Online: 28 January 2026
Change Date: 26 February 2026
Change Type: Update
Change Details: In the original version, the placement of the podcast video is moved between key points and the main text.
Decdlarations
:
: This podcast was supported by Pfizer.
: The authors received no honoraria related to the development of this publication. Eric K. Singhi reports consulting and/or serving on advisory boards with Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Caris Life Sciences, Janssen, Lilly, Novocure, Nuvation Bio, and Regeneron and research funding from Rexanna’s Foundation for Fighting Lung Cancer. Eric S. Nadler reports consulting, speaking, and/or serving on advisory boards with Amgen, AstraZeneca, Bristol Myers Squibb, Catalyst, EMD Serono, Merck, Novocure, Nuvation, and Regeneron.
: Not applicable.
: Eric K. Singhi and Eric S. Nadler made substantial contributions to the development of the podcast, critically reviewed and revised the podcast, and provided final approval of the podcast as submitted.
